Related Experiment Video
Updated: Nov 16, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Two-year toxicity of simultaneous integrated boost in hypofractionated prone breast cancer irradiation: Comparison
Hans Van Hulle1, Eline Desaunois1, Vincent Vakaet2
1Department of Human Structure and Repair, Ghent University, Belgium.
Introduction:
A simultaneous integrated boost (SIB) leads to less acute toxicity. Less is known for late toxicity due to SIB. In this first and only randomized trial, two-years toxicity is analysed.
Materials And Methods:
Physician-assessed toxicity, using the LENT SOMA scale, and photographs, analysed with the BCCT.core software, was examined for 150 patients, randomized between SIB and sequential boost (SEB).
Results:
Differences in physician-assessed two-years toxicity and photographic analysis between SIB and SEB are very small and not significant.
Conclusion:
There is no indication that a SIB leads to an excess in toxicity or worse cosmetic outcome at 2 years.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Treatment Resistant Cancers

